Retraction Note: miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9(Cell Death and Disease, 10.1038/cddis.2017.356);Mir-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing wnt/β-catenin signaling through targeting bcl9

Cell Death and Disease

Volumn 8, Issue 8, 2017, Pages

  Yang, Chao ^a   Xu, Yonghua ^b   Cheng, Feng ^a   Hu, Yuanchang ^a   Yang, Shikun ^a   Rao, Jianhua ^a   Wang, Xuehao ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCL9 PROTEIN, HUMAN; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; MICRORNA; MIRN1301 MICRORNA, HUMAN; TUMOR PROTEIN;

ADULT; AGED; ANIMAL; CANCER GRADING; CELL MOTION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; XENOGRAFT;

ADULT; AGED; ANIMALS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HETEROGRAFTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 85039700096     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/s41419-023-05765-5     Document Type: Erratum

References (32)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–2576.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.
4. Muller C. Hepatocellular carcinoma—rising incidence, changing therapeutic strategies. Wien Med Wochenschr 2006; 156: 404–409.
5. Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011; 253: 453–469.
6. Moss EG. MicroRNAs: hidden in the genome. Curr Biol 2002; 12: R138–R140.
7. Choi E, Hwang KC. MicroRNAs as novel regulators of stem cell fate. World J Stem Cells 2013; 5: 172–187.
8. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350–355.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.
10. Fang L, Yang N, Ma J, Fu Y, Yang GS. MicroRNA-1301-mediated inhibition of tumorigenesis. Oncol Rep 2012; 27: 929–934.
11. Liang WC, Wang Y, Xiao LJ, Wang YB, Fu WM, Wang WM et al. Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform. RNA Biol 2014; 11: 845–854.
12. Bi D, Ning H, Liu S, Que X, Ding K. MiR-1301 promotes prostate cancer proliferation through directly targeting PPP2R2C. Biomed Pharmacother 2016; 81: 25–30.
13. Yun SI, Kim HH, Yoon JH, Park WS, Hahn MJ, Kim HC et al. Ubiquitin specific protease 4 positively regulates the WNT/beta-catenin signaling in colorectal cancer. Mol Oncol 2015; 9: 1834–1851.
14. Carotenuto M, De Antonellis P, Liguori L, Benvenuto G, Magliulo D, Alonzi A et al. H-Prune through GSK-3beta interaction sustains canonical WNT/beta-catenin signaling enhancing cancer progression in NSCLC. Oncotarget 2014; 5: 5736–5749.
15. Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 2002; 109: 47–60.
16. Townsley FM, Cliffe A, Bienz M. Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol 2004; 6: 626–633.
17. Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 1998; 91: 1873–1881.
18. Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 2009; 69: 7577–7586.
19. Deka J, Wiedemann N, Anderle P, Murphy-Seiler F, Bultinck J, Eyckerman S et al. Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res 2010; 70: 6619–6628.
20. de la Roche M, Worm J, Bienz M. The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells. BMC Cancer 2008; 8: 199.
21. Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao JJ, Mani M et al. Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med 2012; 4: 148ra117.
22. Rentoft M, Fahlen J, Coates PJ, Laurell G, Sjostrom B, Ryden P et al. MiRNA analysis of formalin-fixed squamous cell carcinomas of the tongue is affected by age of the samples. Int J Oncol 2011; 38: 61–69.
23. Zhang Y, He X, Liu Y, Ye Y, Zhang H, He P et al. MicroRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. Oncol Rep 2012; 27: 685–694.
24. Smith BN, Bhowmick NA. Role of EMT in metastasis and therapy resistance. J Clin Med 2016; 5: 17.
25. Wu Y, Sarkissyan M, Vadgama JV. Epithelial-mesenchymal transition and breast cancer. J Clin Med 2016; 5: 13.
26. Azoitei N, Pusapati GV, Kleger A, Moller P, Kufer R, Genze F et al. Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumours. Gut 2010; 59: 1316–1330.
27. Xue X, Gao W, Sun B, Xu Y, Han B, Wang F et al. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene 2013; 32: 1724–1734.
28. Moor AE, Anderle P, Cantu C, Rodriguez P, Wiedemann N, Baruthio F et al. BCL9/9 L-beta-catenin signaling is associated with poor outcome in colorectal cancer. EBioMedicine 2015; 2: 1932–1943.
29. Adachi S, Jigami T, Yasui T, Nakano T, Ohwada S, Omori Y et al. Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling. Cancer Res 2004; 64: 8496–8501.
30. Mieszczanek J, de la Roche M, Bienz M. A role of Pygopus as an anti-repressor in facilitating Wnt-dependent transcription. Proc Natl Acad Sci USA 2008; 105: 19324–19329.
31. Peng F, Li TT, Wang KL, Xiao GQ, Wang JH, Zhao HD et al. H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death Dis 2017; 8: e2569.
32. Fang X, Cai Y, Liu J, Wang Z, Wu Q, Zhang Z et al. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal transition and cancer stem-like cell self-renewal. Oncogene 2011; 30: 4707–4720.